Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-30
2011-08-30
Kim, Yunsoo (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388240, C530S391300, C424S141100
Reexamination Certificate
active
08008450
ABSTRACT:
The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
REFERENCES:
patent: 6478825 (2002-11-01), Winterbottom et al.
patent: 6607898 (2003-08-01), Kopreski et al.
patent: 7041499 (2006-05-01), Mathew et al.
patent: 2002/0123617 (2002-09-01), Starling et al.
patent: 2003/0027986 (2003-02-01), Eaton et al.
patent: 2003/0099974 (2003-05-01), Lillie et al.
patent: 2006/0024296 (2006-02-01), Williams et al.
patent: 2009/0238827 (2009-09-01), Williams et al.
patent: 2009/0238835 (2009-09-01), Williams et al.
patent: 2009/0246852 (2009-10-01), Williams et al.
patent: 1 033 401 (2000-09-01), None
patent: WO 96/39518 (1996-12-01), None
patent: WO 98/42738 (1998-10-01), None
patent: WO 99/63088 (1999-12-01), None
patent: WO 00/11150 (2000-03-01), None
patent: WO 00/47602 (2000-08-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 01/16318 (2001-03-01), None
patent: WO 01/46260 (2001-06-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/91793 (2001-12-01), None
patent: WO 02/102993 (2002-12-01), None
patent: WO 02/102994 (2002-12-01), None
patent: WO 03/018621 (2003-03-01), None
patent: WO 03/029423 (2003-04-01), None
patent: WO 2004/029207 (2004-04-01), None
Angel de la Fuente et al. (2001) “Molecular characterization and epression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9,”Blood, 97(11):3513-3520.
Boles et al. (2001) “2B4 (CD244) arti CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cell and other leukocytes,”Immunological Reviews, 181:234-249.
Boles et al. (2001) “Molecular cloning of CS1, a novel human natural keller cell receptor belonging to the CD2 subset of the immunogIobulin superfamily,”Ingmunogenetics, 52:302-307.
Bouchon et al. (2001) “Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family”;Journal of Immunolog, 167:5517-5521.
Genbank accession AB027233 (May 1999).
Genbank accession AF291815 (Aug. 2000).
Genbank accession AF390894 (Jun. 2001).
Genbank accession AF467909 (Jan. 2002).
Genbank accession AJ271869 (Mar. 2000).
Genbank accession H73135 (Oct. 1995).
Genbank accession H74227 (Oct. 1995).
Genbank accession NM—021181 (Mar. 2005).
Hillier et al. (1996) “Generation and analysis of 280,000 human expressed sequence tags,”Genome Research, 6:807-828.
Kumaresan et al, (2002) “CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function,”Molecular Immunology, 39:1-8.
Leo et al. (1992) “Multiparameter analysis of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+is the common phenotype of myeloma cells,”Annals of Hematology, 64;132-139.
Murphy at al. (1999) “An early response gene (19A) which encodes a novel immunoglobulin superfamily member with structural similarity to CD2,”Immunology, Supplement 1:60.
Murphy et al. (2002) “A novel immunoglobulin superfamily rceptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion,”Biochem. J., 361:431-436.
Murphy et al. (1990) “Cell-type-specific early reponse gen expression during plasmacytoid differentiation of human B lymphocytic leukemia cells,”Biochimica et Biophysica Acta; 1049:261-271.
Ni et al. (1996) “Imrmunological abnormality in C3H/HeJ mice with heritable inflammatory bowel disease,”Cellular Immunology, 169:7-15.
Ogura et al. (2001) “A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease,”Nature, 411:603-606.
Presta et al. (2002) “Engineering therapeutic antibodies for improved function,”Biochem Society Transactions, 30(4):487-490.
Ruiz-Argulles et al. (1994) “Cell surface markers in multiple myeloma,”Mayo Clinic Proc., 69:684-690.
Shields et al. (2001) “High resolution mapping of the binding site on human IgGI for FcγRI, FcγRIII, and FcRn and design of IgGI variants with improved binding to the FcγR,”The Journal of Biological Chemistry, 276:6591-6604.
Shields et al. (2002) “Lack of fucose on human IgGIN-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular tocicity,”The Journal of Biological Chemistry, 277:26733-26740.
Shinkawa et al. (2003) “The absence of fucose but not the presence of galactose or bisectingN-acetylgilucosamine of human IgGI complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity,”The Journal of Biological Chemistry, 278(5):3466-3473.
Sidorenko et al. (2003) “The dual-function CD150 receptor subfamily: the viral attraction,”Nature Immunology, 4(1):19-24.
Tangye et al. (2003) “Functional requirements for interactions between CDS4 and Src homology 2 domain-containing protein and their contribution to human T cell activation,”The Journal of Immunology, 1761:2485-2495.
Tovar et al. (2002) “Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors,”Immunogenetic, 54(6):394-402.
Tricot et al. (1995) “Poor prognosis in multiple myeloma is assosicated only with partial or complete deletions of chromosome 13 or abnormalities involving 11 q and not with other karyotype abnormakities,”Blood, 86:4250-4256.
Xu et al. (2000) “In vivo characterization of five humanized OKT3 effector function variant antibodies,”Cellular Immunology, 200(1)16-26.
Declaration of Gary Starling under 37 C.F.R. § 1.132 dated Oct. 22, 2008 with Figure 1.
Van der Laan et al. (2002)Journal of Neuroscience Research67:191-199.
Landolfi Nicholas F.
Liu Gao
Tso J. Yun
Williams Marna
Abbott Biotherapeutics Corp.
Dechert LLP
Kim Yunsoo
LandOfFree
Therapeutic use of anti-CS1 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of anti-CS1 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of anti-CS1 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2796247